1. Scrip
  2. >>Business

Sarepta Smacked By FDA's Curiously Timed Compassionate Use Revisions

 
• By Donna Young

Sarepta Therapeutics Inc. investors panicked over the FDA's June 2 release of revised expanded access guidances – worried the action was in preparation for the agency to reject the company's Duchenne muscular dystrophy drug eteplirsen, whose verdict was curiously delayed last week.

While the FDA insisted there was absolutely no connection to its June 2 release of its revised expanded access guidances, which include the finalization of a streamlined process for doctors to request "compassionate use" of investigational medicines, and the curiously timed delay last week of the agency's decision on Sarepta Therapeutics Inc.'s experimental Duchenne muscular dystrophy (DMD) treatment eteplirsen, Wall Street was unconvinced.

Indeed, most analysts and investors interpreted the FDA's updates to its expanded access program as having direct implications for Sarepta...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

J&J And Novartis On 2025’s Biggest M&A Deals And What Can Derail A Buyout

 
• By Andrew McConaghie

Three big pharma business development heads at the recent Jefferies conference discussed their activities in 2025, and offered some advice to potential partners on how to avoid deal talks breaking down.

Sanofi Flies The Flag For France

 
• By Kevin Grogan

The Paris-headquartered giant has put the spotlight on its extensive investments at home.

Some CAR-Ts Are Thriving While Others Are Falling Behind. Why?

 
• By Alaric DeArment

With Gilead reporting that both of its approved CAR-Ts saw sales declines as other products saw growth, a mixture of different competitive headwinds seems to be behind the disparities.

Finance Watch: Lilly Toes The $1 Trillion Valuation Line

 
• By Mandy Jackson

Public Company Edition: Lilly’s obesity franchise makes it the highest-valued health care company in the US. Also, Genmab accesses $4.5bn to fund its $8bn Merus buy, Moderna locks in a $1.5bn credit facility and Ionis sells $700m worth of notes.

More from Scrip

Pipeline Watch: Eight Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Sibeprenlimab’s US Accelerated Approval Drives IgAN Competition Forward

 
• By Lisa Takagi

Following US approval of its first-in-class drug for IgAN sibeprelimab, Otsuka is planning an sNDA for an autoinjector in 2026 and is in talks with regulatory authorities in Japan and Europe.

The Rise of China Biopharma – Five Themes In 2025

 
• By Andrew McConaghie

The growth of China’s biopharma sector has been perhaps the most significant sector trend this year – Scrip outlines five themes that have emerged during 2025 and in discussions at the recent Jefferies conference in London.